Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh chemotherapy in favor of a more effective, targeted approach.

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Among these developments is trastuzumab deruxtecan (brand name: Enhertu), which offers new hope specifically for patients who harbor HER2 mutations in their lung cancer, a type once challenging to ...

Confirmed objective response rate (ORR) with ENHERTU plus pertuzumab was ... the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to become a new ...

Confirmed objective response rate (ORR) with ENHERTU plus pertuzumab was 85.1% versus 78. ... the DESTINY-Breast09 results show trastuzumab deruxtecan combined with pertuzumab has the potential to ...